Consun Pharmaceutical Group Limited (1681.HK) AI-Powered Stock Analysis
See how Consun Pharmaceutical Group Limited scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
1681.HK●HKSE
HealthcareDrug Manufacturers - Specialty & Generic
HK$13.58
HK$0.60(4.23%)
Hong Kong Market opens in 41h 52m
Consun Pharmaceutical Group Limited (1681.HK)
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerConsun Pharmaceutical Group Limited (1681.HK) Stock Overall Grade
Consun Pharmaceutical Group Limited’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Consun Pharmaceutical Group Limited's overall stock rating.
Forecast
B+Score
77/100Financial Growth
CScore
40/100Fundamental Growth
B+Score
78/100Key Ratios
A+Score
97/100Sector Comparison
AScore
85/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100Consun Pharmaceutical Group Limited (1681.HK) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 77/100 (B+), reflecting high confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (78/100, B+) highlight its stability, while Key Ratios (97/100, A+) and Sector Comparison (85/100, A) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Consun Pharmaceutical Group Limited stock grade, including financials, comparisons, and forecasts.